IGFBP-3 Protein, Human (HEK293, His)

IGFBP-3 protein is a part of IGFBP that significantly prolongs IGF half-life and modulates growth effects in cell culture. It inhibits or stimulates IGF-induced cellular responses by changing the kinetics of interaction with cell surface receptors. IGFBP-3 Protein, Human (HEK293, His) is the recombinant human-derived IGFBP-3 protein, expressed by HEK293 , with N-His labeled tag. The total length of IGFBP-3 Protein, Human (HEK293, His) is 264 a.a., with molecular weight of 40-45 kDa.

IGFBP-3 Protein, a member of the insulin-like growth factor-binding proteins (IGFBPs), plays a crucial role in extending the half-life of insulin-like growth factors (IGFs) and modulating their growth-promoting effects on cell culture. With the capacity to either inhibit or stimulate IGF-induced cellular responses, IGFBP-3 exerts its regulatory influence by altering the interaction dynamics between IGFs and their respective cell surface receptors. Additionally, IGFBP-3 exhibits IGF-independent antiproliferative and apoptotic effects mediated by its receptor TMEM219/IGFBP-3R. Furthermore, IGFBP-3 inhibits the positive effect of humanin on insulin sensitivity and promotes testicular germ cell apoptosis. Interactions with XLKD1 and the formation of a ternary complex with IGF1 or IGF2 and a glycoprotein (ALS) further underscore the diverse roles of IGFBP-3. The intricate network of interactions, including those with humanin and TMEM219, highlights the multifaceted nature of IGFBP-3 in modulating cellular processes and signaling pathways associated with growth and apoptosis.

1. Measured by its binding ability in a functional ELISA. Immobilized human IGF2 at 10 μg/mL (100 μl/well) can bind biotinylated Human His-IGFBP3, The EC₅₀ of biotinylated Human His-IGFBP3 is ≤18 ng/mL.
2. Measured by its binding ability in a functional ELISA. Immobilized human IGF1 at 10 μg/mL (100 μl/well) can bind biotinylated Human His-IGFBP3, The EC₅₀ of biotinylated Human His-IGFBP3 is ≤24 ng/mL.
3. Measured by its ability to inhibit the biological activity of IGFI or IGFII on MCF7 human breast adenocarcinoma cells (Karey, K.P. et al. (1988) Cancer Research 48:4083.). The ED₅₀ for this effect is typically 0.05-0.2 μg/mL in the presence of 14 ng/mL human IGFII.

Human

HEK293

N-His

P17936 (G28-K291)

3486  [NCBI]

40-45 kDa

Greater than 95% as determined by reducing SDS-PAGE

Solution.

Supplied as a 0.2 μm filtered solution of PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.

<1 EU/μg, determined by LAL method.

N/A.

Stored at -80°C for 1 year. It is stable at -20°C for 3 months after opening. It is recommended to freeze aliquots at -80°C for extended storage. Avoid repeated freeze-thaw cycles.

Shipping with dry ice.